Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network metaanalysis

Background: To answer which epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is the best choice for advanced non-small cell lung cancer (NSCLC) EGFR mutants. Results: 16 phase III randomized trials involving 2962 advanced NSCLC EGFR mutants were enrolled. Multiple treatment comp...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncotarget
Main Authors: Zhang, Yaxiong, Sheng, Jin, Yang, Yunpeng, Fang, Wenfeng, Kang, Shiyang, He, Yang, Hong, Shaodong, Zhan, Jianhua, Zhao, Yuanyuan, Xue, Cong, Ma, Yuxiang, Zhou, Ting, Ma, Shuxiang, Gao, Fangfang, Qin, Tao, Hu, Zhihuang, Tian, Ying, Hou, Xue, Huang, Yan, Zhou, Ningning, Zhao, Hongyun, Zhang, Li
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2016
נושאים:
Research Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4990517/
https://ncbi.nlm.nih.gov/pubmed/26933807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7713
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים